[Hyderabad, April 25th, 2025] — The global cancer biomarkers market is projected to grow from USD 18.6 B in 2023 to USD 48.3 Bn by 2031 (12.7% CAGR), according to ClearView Market Insights. This 160% expansion reflects oncology’s shift toward blood-based diagnostics and AI-powered decision tools.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-cancer-biomarkers-market/
Section 1: The Biomarker Revolution
1.1 Liquid Biopsy Tipping Point
- 2024 Medicare Coverage: Guardant360® is now reimbursed for all solid tumors.
- Tissue-Free TMB: Foundation Medicine’s assay achieves 95% concordance.
1.2 AI’s Disruptive Role
- Paige Prostate: Cuts false negatives by 45%.
- Tempus xF: Matches patients to trials 30% faster.
Section 2: 2024 Market Shifts
2.1 Multi-Cancer Early Detection
- Galleri®: Detects 50+ cancers at Stage I/II.
- Freenome: AI integrates protein + DNA + RNA signals.
2.2 Pharma Partnerships
Collaboration | Goal | Impact |
Roche + Grail | MCED commercialization | 10M tests/year by 2027 |
BMS + Natera | ctDNA for Opdivo® monitoring | 50% trial enrollment boost |
Section 3: Future Roadmap
2024-2026:
- 50% of NSCLC testing shifts to liquid biopsies.
- AI-pathology adopted in 80% of NCCN centers.
2027-2031:
- MCED screens 20M patients/year.
- Epigenetic biomarkers dominate AML/lymphoma.
For more insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
